Have you seen this news?16 Jul 2013 11:23
JSC "Pharmsynthez" displays the first product on the market in Central America
July 2, 2013, St. Petersburg - JSC "Pharmsynthez» (MICEX - LIFE) (hereinafter "Pharmsynthez" or the "Company"), a leading Russian biopharmaceutical company that specializes in research, production, and distribution of pharmaceutical products, today announced that the Company's subsidiary AS Kevelt, has brought to market the first product of Central America - Prostenongel. In addition, together with the German company Transopharm (the "Partner") "Pharmsynthez" defined the first customers in the Republic of Costa Rica.
In cooperation with the Partner "Pharmsynthez" is promoting the company's product to the market, intratservikalno gel Prostenongel 2mg / 3,5 g (dinoprostone), which is used for induction of labor and appropriate medical indications. The product has been well received and local authorities announced their intention to conclude a contract for the supply of 10,000 packages Prostenongelya.
In accordance with local regulatory provisions Prostenongel now undergoing registration, due to the design of which will be possible to execute orders for the supply of products and the expansion of the Company's presence in the region with access to the markets of neighboring countries, such as Panama.
Dmitry Genkin, Chairman of the Board of Directors of "pursuing its goal", said: "We are pleased with the conclusion of our first product on the market in Central America. In the Republic of Costa Rica, we have received positive feedback on our products and noted the presence of demand and interest in the organization of supply. This gives us the confidence and intention to quit and to other countries in the region. Expand the market of our products is one of the key objectives of the Board of Directors of the Company, and we are convinced that the expansion into new territories will create additional value for our shareholders. "
Sign In
Follow the stocks
